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safety, effectiveness, and utility of carotid reoperations as
well as about their appropriate indications.7,8
Furthermore, with the advent of carotid angioplasty
and stenting, some authors have proposed that recurrent
carotid stenosis may be more effectively treated with this
method rather than with direct surgical reconstruc-
tion.6,9,10 Although the complication rates and the dura-
bility of carotid angioplasty and stenting for recurrent
carotid stenosis remain to be clearly demonstrated, it
seems likely that the results of catheter-based intervention
will increasingly be compared with those of reoperations.
Consequently, the current study was undertaken to deter-
mine the postoperative mortality and stroke rates associ-
ated with reoperations for recurrent carotid stenosis at our
own center, to document late survival and the stroke rate
in these patients, and to identify clinical factors that may
influence their ultimate outcome.
PATIENTS AND METHODS
Using the computerized registry of the Department of
Vascular Surgery at the Cleveland Clinic, we identified
199 consecutive patients who underwent 206 carotid
reoperations (REDOCEAs) for recurrent stenosis from
January 1989 through December 1999. These reopera-
tions represented 6% of the 3360 carotid endarterectomies
Carotid endarterectomy has been demonstrated to be
an effective and durable treatment for both symptomatic
and asymptomatic internal carotid stenosis.1,2 Never-
theless, largely because of patient and physician awareness,
the aging population, and the wide availability of reliable
noninvasive carotid testing, some patients are identified
who require carotid reoperation for recurrent carotid
stenosis after prior carotid endarterectomy. Carotid reop-
erations are often considered to be more technically
demanding than primary carotid endarterectomy,3,4 and
some authors have reported higher morbidity rates for
reoperations than for primary carotid endarterectomy.5,6
Consequently, controversy currently exists about the
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Purpose: This study was undertaken to determine the safety and efficacy of reoperations for recurrent carotid stenosis
(REDOCEA) at the Cleveland Clinic.
Materials and Methods: From 1989 to 1999, 206 consecutive REDOCEAs were performed in 199 patients (131 men,
68 women) with a mean age of 68 years (median, 69 years; range, 47-86 years). A total of 119 procedures (57%) were
performed for severe asymptomatic stenosis, 55 (27%) for hemispheric transient ischemic attacks or amaurosis fugax,
26 (13%) for prior stroke, and 6 (3%) for vertebrobasilar symptoms. Eleven REDOCEAs (5%) were combined with
myocardial revascularization, and another 19 (9%) represented multiple carotid reoperations (17 second reoperations
and 2 third reoperations). Three REDOCEAs (1%) were closed primarily, and nine (4%) required interposition grafts,
whereas the remaining 194 (95%) were repaired with either vein patch angioplasty (139 [68%]) or synthetic patches
(55 [27%]). Three patients (2%) were lost to follow-up, but late information was available for 196 patients (203 oper-
ations) at a mean interval of 4.3 years (median, 3.9 years; maximum, 10.2 years).
Results: Considering all 206 procedures, there were 7 early (< 30 days) postoperative neurologic events (3.4%), includ-
ing 6 perioperative strokes (2.9%) and 1 occipital hemorrhage (0.5%) on the 12th postoperative day. Seventeen addi-
tional neurologic events occurred during the late follow-up period, consisting of eight strokes (3.9%) and nine transient
ischemic attacks (4.4 %). With the Kaplan-Meier method, the estimated 5-year freedom from stroke was 92% (95% CI,
88%-96%). There were two early postoperative deaths (1%), both from cardiac complications after REDOCEAs com-
bined with myocardial revascularization procedures. With the Kaplan-Meier method, the estimated 5-year survival was
81% (range, 75%-88%). A univariate Cox regression model yielded the presence of coronary artery disease as the only
variable that was significantly associated with survival (P = .024). The presence of pulmonary disease (P = .036), dia-
betes (P = .01), and advancing age (P = .006) was found to be significantly associated with stroke after REDOCEA.
Causes of 53 late deaths were cardiovascular problems in 25 patients (47%), unknown in 14 (26%), renal failure in 4
(8%), stroke in 3 (6%), and miscellaneous in 7 (13%).
Conclusions: We conclude that REDOCEA may be safely performed in selected patients with recurrent carotid stenosis
and that most of these patients enjoy long-term freedom from stroke. (J Vasc Surg 2001;34:5-12.)
performed during the same study period. Retrospective
data were collected from the hospital records, and long-
term information was obtained during subsequent office
visits or by telephone contact with the patients, their
immediate families, or their local physicians. End points
were defined as the clinical status at the time of the most
recent follow-up. In addition to death, outcome variables
included transient ischemic attack (TIA) or stroke, occur-
ring either during the perioperative period or during late
surveillance, and the detection of restenosis. Follow-up
was complete for 196 patients, representing 203 opera-
tions. The remaining three patients were considered lost
after hospital discharge. Two of these were alive and stroke
free on the 2nd and 27th postoperative days, whereas the
remaining patient, who sustained a postoperative stroke
after combined REDOCEA and myocardial revasculariza-
tion, was lost after the 14th postoperative day. The median
follow-up period was 3.9 years (mean, 4.3 years; maxi-
mum, 10.2 years).
The study group consisted of 131 men and 68
women, with a mean age of 68 years (median, 69 years;
range, 47-86 years) at the time of their reoperations. A
total of 160 patients (80%) had clinical evidence of coro-
nary artery disease (CAD), defined as a convincing history
of prior myocardial infarction or angina, or either Q waves
or ischemic ST-T wave changes on a 12-lead electrocar-
diogram. A total of 167 patients (84%) were hypertensive,
132 (66%) were hyperlipidemic, 98 (49%) smoked ciga-
rettes, 51 (26%) were diabetic, 39 (20%) had chronic
obstructive pulmonary disease (COPD), and 37 (19%)
had a history of congestive heart failure.
A total of 119 procedures (57%) were performed for
severe asymptomatic stenosis (≥ 80%, or ≥ 60% if the con-
tralateral internal carotid artery was occluded), whereas 55
(27%) were done for hemispheric TIAs or amaurosis
fugax, 26 (13%) for prior stroke, and 6 (3%) for verte-
brobasilar symptoms.
Considering the 206 prior carotid operations leading
to the index reoperation considered in this series, 94 pro-
cedures (46%) had been performed at the Cleveland
Clinic, whereas 109 prior operations (53%) had been per-
formed elsewhere. The site of two prior operations (1%)
could not be determined from available records, and one
additional patient (0.5%) had an original carotid
endarterectomy elsewhere followed by a carotid reopera-
tion at the Cleveland Clinic in 1988. A total of 193
patients in this series had one reoperation at the Cleveland
Clinic, whereas six patients had more than one reoperation
at this center. Four of these patients had a primary reop-
eration and an ipsilateral second reoperation. Another had
a primary reoperation, an ipsilateral second reoperation,
and a contralateral second reoperation. The remaining
patient, whose primary reoperation had been done else-
where, had a second reoperation and a subsequent ipsilat-
eral third reoperation at this center. A total of 109 prior
carotid operations (53%) were closed primarily, and in 85
closures (41%) patches were used (63 vein, and 22 syn-
thetic). In two prior procedures (1%) interposition grafts
(1 saphenous vein and 1 polytetrafluoroethylene) were
used, whereas the closure method of the remaining 10
prior operations (5%) could not be determined.
Considering the 85 patch closures, saphenous vein was
used in 63 (74%), polyester fiber (Dacron) in 14 (16%),
polytetrafluoroethylene in 4 (5%) and a nonspecified syn-
thetic material in 4 (5%).
The severity of preoperative internal carotid stenosis
was evaluated with ultrasonography, angiography, or both
and was calculated by means of an estimation of the diam-
eter of residual lumen compared with that of the carotid
bulb. With this method, an angiographic stenosis resulting
in 80% diameter reduction is equivalent approximately to
60% stenosis by the North American Symptomatic Carotid
Endarterectomy Trial criteria.1,11 The ultrasound criteria
for 80% to 99% internal carotid stenosis required both a
peak systolic velocity more than 240 cm/s and an end-
diastolic velocity of 135 cm/s or more; for 60% to 79%
internal carotid stenosis, a peak systolic velocity more than
150 but less than 240 cm/s with spectral broadening; for
40% to 59% internal carotid stenosis, a peak systolic veloc-
ity more than 105 but less than 150 cm/s with spectral
broadening; for 20% to 39% internal carotid stenosis, a
peak systolic velocity less than 105 cm/s with spectral
broadening; and for 0% to 19% internal carotid stenosis, a
peak systolic velocity less than 105 cm/s with no spectral
broadening. A total of 177 procedures (86%) were per-
formed for 80% to 99% stenosis, 19 (9%) for 60% to 79%
stenosis, 8 (4%) for 40% to 59% stenosis, and 1 (0.5%) for
20% to 39% ulcerated stenosis. Forty-two (20%) of the
contralateral internal carotid arteries were found to be
occluded, 17 (7%) had 80% to 99% stenosis, 32 (16%) had
60% to 79% stenosis, 31 (15%) had 40% to 59% stenosis,
26 (13%) had 20% to 39% stenosis, and 57 (28%) had 0%
to 19% stenosis by means of preoperative ultrasonography,
angiography, or both. A total of 183 (90%) carotid arter-
ies were imaged with both ultrasonography and angiogra-
phy, whereas 7 procedures (3%) were performed on the
basis of ultrasonography alone and the remaining 15 (7%)
on the basis of angiography alone. The imaging method
for one patient could not be determined from the available
records. For the purpose of analysis, angiography results
were used when available; otherwise, ultrasound data were
used.
A total of 107 patients (54%) in this series had at some
time undergone myocardial revascularization. Eighty-five
patients (43%) had coronary artery bypass grafting
(CABG) alone, 8 (4%) have had percutaneous translumi-
nal coronary angioplasty alone, and 14 (7%) had both.
Eleven REDOCEAs (5%) were performed as combined
procedures in conjunction with CABG.
Considering all 206 REDOCEA procedures, 176
(86%) were the first reoperations alone, 11 (5%) were
combined with myocardial revascularization, and another
19 (9%) represented multiple carotid reoperations (17 sec-
ond reoperations and 2 third reoperations). Nine
REDOCEAs (4%) required interposition grafts, and the
remaining 197 (96%) had endarterectomies. Three
JOURNAL OF VASCULAR SURGERY
6 O’Hara et al July 2001
endarterectomies (1%) were closed primarily, whereas 194
(95%) were repaired by means of patch angioplasty with
either vein (139 [68%]) or synthetic patches (55 [27%]).
Statistical analysis. Kaplan-Meier estimates of sur-
vival were generated for overall survival, freedom from
stroke, and freedom from detection of restenosis. The uni-
variate association of potential baseline risk factors with
time to stroke and mortality was assessed with Cox pro-
portional hazards regression models and the likelihood
ratio χ2 test. The clinical features considered in this analy-
sis were age, cigarette smoking, CAD, COPD, prior
CABG or percutaneous transluminal coronary angioplasty,
diabetes, sex, hypertension, hyperlipidemia, patch mate-
rial, plaque histology, and renal function (serum creatinine
level > 2.0 mg/dL). For each factor, risk ratios and their
95% CIs were calculated to indicate the risk of the out-
come at any point in time in the risk group compared with
the reference group. For continuous variables, the risk
ratio compares patients with a specified increment in the
variable with those without the increment (eg, age 70 ver-
sus age 60).
In addition to estimating freedom from detection of
restenosis, we also attempted to estimate the actual free-
dom from restenosis. In simulations, for each restenosis
we assigned a random event date between the operation
(or previous nonevent visit) and detection dates. One-, 3-,
and 5-year freedom from restenosis estimates were
obtained from each of 1000 simulations. The median and
2.5th and 97.5th percentiles at each time were used as our
best estimate of restenosis, with a 95% CI. Multivariable
models were used for each outcome. Miscellaneous analy-
ses with traditional methods for assessing associations were
also performed. A significance level of P = .05 was used for
each hypothesis. SAS statistical software (SAS Institute,
Inc, Cary, NC) was used for all analyses.12-14
RESULTS
Pathology. Considering all 206 REDOCEAs in this
series, the underlying pathologic process, as determined
from the pathology reports in the medical records, was
recurrent atherosclerosis for 175 procedures (85%),
whereas 26 reoperations (13%) were performed for myoin-
timal fibroplasia. The pathologic diagnosis for three reoper-
ations (1%) could not be determined from available records,
and two additional procedures (1%) were performed
because of an intimal injury and a thrombus formation at a
previous carotid endarterectomy site. The median interval
from the prior operation to the index reoperation was sig-
nificantly longer (7.4 years) for the atherosclerosis group
than that (1.3 years) for the myointimal fibroplasia group
(P < .001, 2-tailed Wilcoxon rank sum test).
Early mortality and morbidity. Considering all 206
procedures, there were 7 early (< 30 days) postoperative
neurologic events (3.4%), including 6 strokes (2.9%) and
1 occipital hemorrhage (0.5%) on the 12th postoperative
day. One early postoperative stroke (9.1%) occurred
among the 11 patients who underwent combined REDO-
CEA with myocardial revascularization, and 5 (2.6%)
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occurred among the 195 patients who underwent non-
combined REDOCEA (P = .28, Fisher exact test). Two
early postoperative strokes (1.7%) occurred among the
119 symptom-free patients, and 4 (4.6%) occurred among
the 87 patients with symptoms (P = .24, Fisher exact test).
The patient with the occipital hemorrhage had amaurosis
fugax preceding a noncombined operation. Two patients
(1.0%) were documented to have cranial nerve injuries
(Table I).
There were two early postoperative deaths (1.0%);
both were caused by cardiac complications after combined
REDOCEA with myocardial revascularization. Conse-
quently, two (18.2%) of 11 patients requiring combined
procedures died in the early postoperative period, whereas
there were no early deaths after the 195 noncombined
REDOCEAs (P = .003, Fisher exact test).
Late survival and freedom from stroke. Late sur-
vival data for all 199 patients are illustrated in Fig 1. The
Kaplan-Meier 5-year survival for the entire series was 82%
(95% CI, 75%-88%). Because six patients had more than
one index reoperation in this series, these patients were
censored at the time of their first subsequent reoperation.
The probable causes for 53 late deaths are summarized in
Table II.
An additional 17 neurologic events occurred during
the late follow-up period, consisting of eight strokes (4%)
and nine TIAs (5%). As illustrated in Fig 2, the 5-year free-
dom from stroke estimated with the Kaplan-Meier
method was 92% (95% CI, 88%-96%). For this analysis, the
event was stroke, and patients were censored at the first
occurrence of loss to follow-up, the first occurrence of
another reoperation, or death.
Recurrent stenosis. A total of 116 patients who
underwent 121 procedures (59%) underwent at least one
follow-up duplex ultrasound examination of their carotid
reconstruction after REDOCEA during a mean interval of
Fig 1. Cumulative survival (Kaplan-Meier method) for 199
patients in entire series who underwent carotid endarterectomy
(open circles represent patients censored at subsequent reopera-
tion). Shaded area is 95% confidence band.
3.4 years (median, 3.1 years; range, 0.1-9.9 years). When
more than one study was available, the most recent ultra-
sound scan was considered for analysis. Seven of the ipsi-
lateral internal carotid arteries (6%) were found to be
occluded, 4 (3%) had 80% to 99% stenosis, 8 (7%) had 60%
to 79% stenosis, 6 (5%) had 40% to 59% stenosis, 19 (16%)
had 20% to 39% stenosis, and 77 (63%) had 0% to 19%
stenosis by means of postoperative ultrasonography.
Kaplan-Meier estimates of restenosis detection and simu-
lated freedom from actual restenosis rates are summarized
in Table III. The five patients in this subset with more
than one reoperation were censored at the time of the sub-
sequent reoperation. Data about late freedom from docu-
mented restenosis for all 116 patients (121 procedures)
are illustrated in Fig 3. The cumulative (Kaplan-Meier
method) 5-year estimate of freedom from ≥ 60% resteno-
sis detection was 83% (95% CI, 74%-93%) (Fig 3, A), and
the 5-year estimate of freedom from ≥ 80% restenosis
detection was 89% (95% CI, 80%-97%) (Fig 3, B).
Because the actual time of restenosis was likely to have
occurred before its detection, the actual freedom from
restenosis estimates are likely to be lower than those cal-
culated with the date of ultrasound detection. Conse-
quently, an attempt was made to estimate the true time to
restenosis through computer simulation where the actual
date of restenosis was chosen to be a random date between
the index operation and the date of detection. Kaplan-
Meier estimates of freedom from restenosis were then cal-
culated at 1, 3, and 5 years for each of 1000 simulations.
These results are displayed in Fig 3 and are similar to the
cumulative duplex restenosis rates derived with the dates
of detection by carotid ultrasound (Table III). These
observations suggest that the estimates of detected
restenosis are probably only slightly higher than the actual
restenosis rate.
Univariable analysis. Through univariable analysis
we identified the presence of CAD (P = .024) as being sig-
nificantly associated with death at any time after REDO-
CEA (Table IV). We also identified the presence of
diabetes (P = .01), COPD (P = .036), and advancing age
(P = .006) as being significantly associated with the risk of
stroke at any time after REDOCEA (Table V). The small
number of stroke events did not permit fitting a multivari-
able model for risk of stroke. The Kaplan-Meier 3-year
survival or stroke-free survival estimates for patients with
and without these clinical variables are summarized in
Table V.
DISCUSSION
Reoperation is uncommonly required for recurrent
stenosis after carotid endarterectomy. In our own series,
carotid reoperations comprise only 6% of the 3360 carotid
endarterectomies performed in our department from 1989
through 1999. Ninety-four of the original procedures were
performed at our own center. As a result, the minimum
incidence requiring reoperation among our own patients is
approximately 2.8%. There is a wide variation in the
reported incidence of recurrent carotid stenosis depending
on the diagnostic technique used, the intensity and dura-
tion of follow-up, and the definition of recurrence used.15
With the use of noninvasive methods, the reported inci-
dence is generally 10% to 15%; however, only 1% to 3% of
these patients require reoperation, usually for neurologic
symptoms or hemodynamically significant stenoses.3,15,16
The patients in our series had severe recurrent carotid
occlusive disease. Nearly all (95%) of the internal carotid
arteries operated on had at least 60% to 79% stenosis doc-
umented through duplex ultrasound scan or angiography,
and 86% had ≥ 80% stenosis. Nearly half (43%) had symp-
toms, usually despite antithrombotic therapy.
Our data confirmed that recurrent carotid stenosis due
to myointimal hyperplasia occurred at a significantly
shorter interval after the original carotid operation than
did restenosis resulting from atherosclerosis, a finding
observed by others.17,18 Although our data might be
interpreted to suggest that patients with myointimal dis-
ease may have more of a risk for stroke after REDOCEA
(Table V), the difference did not achieve statistical signifi-
cance (P = .08), possibly because of the low event rate.
Nevertheless, this finding seems to support the conserva-
tive approach to asymptomatic early recurrent carotid
stenosis advocated by some authors.3,7,8
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Table I. Early (< 30 days) complications after 206 carotid operations
Symptomatic (n = 87) Asymptomatic (n = 119) Total (n = 206)
Postoperative neurologic event No. % No. % No. %
Stroke 4 4.6 2 1.7 6 2.9
Occipital hemorrhage 1 1.1 0 0 1 0.5
Cranial nerve injury 1 1.1 1 0.8 2 1.0
Total 6 6.8 3 2.5 9 4.4
Table II. Causes of 53 late (> 30 days) postoperative
deaths
Cause No. %
Cardiovascular 25 47
Unknown 14 26
Renal failure 4 8
Stroke 3 6
Miscellaneous 7 13
Total 53 100
The 30-day operative mortality rate for all patients
who underwent REDOCEA was 1% in our series, and
both of these patients underwent REDOCEA combined
with myocardial revascularization. There were no early
postoperative deaths among the patients who underwent
REDOCEA alone. Furthermore, the operative mortality
rate for these patients was similar to that (0.5%) for a con-
temporary series of our patients undergoing primary
CEA.19 Additionally, the perioperative stroke rate for redo
patients in our series (2.9% for all patients, 2.6% for non-
combined reoperations) was also similar to that (2.2%) for
primary patients.19 In contrast to some reports3 our
observations support the conclusion that the early results
of REDOCEA are as good as they are for primary patients,
a finding confirmed by others.20
Although the median age of the patients in our series
was 69 years, their cumulative 3-year survival after REDO-
CEA (89%) compares favorably with that (87% no patch,
80% patch) estimated for the patients in our own experi-
ence who underwent primary carotid operations and
whose median age was about 3 years younger.21
Furthermore, their 5-year freedom from stroke was 92%,
indicating that most of these patients lived the rest of their
lives without strokes.
Although the early and late results of angioplasty and
stenting for recurrent carotid stenosis have yet to be
clearly demonstrated, reports of small series of patients
have shown early stroke rates ranging from 0% to 4% asso-
ciated with endovascular treatment of recurrent carotid
stenosis.6,10,22 A retrospective, multicenter registry review
of 338 patients who underwent carotid stenting for recur-
rent carotid stenosis, with a mean follow-up interval of
only 14 months, reported a periprocedural combined
stroke and death rate, considering only the hemisphere at
risk, of 3.7%.9 In contrast, our combined stroke and death
rate (2.6% for reoperations not combined with cardiac
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operations) for REDOCEA patients is based on all strokes
and is not confined to only the hemisphere at risk.
Furthermore, it appears to have improved compared with
that (4.6%) of our previous report16 of 15 years ago,
emphasizing the need to compare endovascular treatments
with current surgical results. Late durability of REDO-
CEA also appears to be excellent with the 5-year freedom
from stroke rate of 92%.
Although nearly two thirds of our patients returned
for at least one postoperative duplex examination, objec-
tive, noninvasive follow-up was not complete for all
patients in this series. Nevertheless, 89% of those patients
who continued their surveillance remained free from ultra-
sound detection of ≥ 80% restenosis for 5 years.
Another limitation of our study is its retrospective
design. The relationship of the late strokes to carotid
bifurcation disease remains uncertain because the hemi-
Fig 2. Cumulative freedom from stroke (Kaplan-Meier method)
for 199 patients in entire series who underwent carotid
endarterectomy (open circles represent patients censored at subse-
quent reoperation). Shaded area is 95% confidence band.
Fig 3. Cumulative freedom from detection of restenosis (Kaplan-
Meier method) for 116 patients (121 reoperations) who were
evaluated with late carotid ultrasonography (open circles represent
patients censored at subsequent reoperation; solid circles represent
simulated freedom to actual restenosis with 95% CIs). Shaded
area is 95% confidence band. A, At least 60% restenosis. B, At
least 80% restenosis.
A
B
spheric distribution of all of the late strokes often could
not be accurately determined. Moreover, the observation
that three late deaths (6%) were caused by strokes under-
scores the fact that REDOCEA cannot prevent all late
strokes, because some undoubtedly are caused by other
factors, such as cardiac arrhythmias or hypertension.
Finally, the etiologies of 14 late deaths (26%) were unde-
termined, and therefore, it is possible that some were
related to stroke.
In an attempt to develop guidelines for the selection
of patients likely to derive long-term benefit from REDO-
CEA, we investigated clinical variables associated with
patient survival and freedom from stroke with univariable
analysis. Only the preoperative clinical diagnosis of CAD
emerged as a significant independent variable associated
with death at any time after REDOCEA. Consequently,
we continue to advocate an aggressive approach to the
diagnosis and treatment of associated CAD in these
patients.
The clinical variables that emerged from the univari-
able analysis as significant independent predictors of stroke
at any time after REDOCEA were diabetes, advancing
age, and COPD. Patients with the clinical diagnosis of dia-
betes were found to be 3.5 times more likely to have a
stroke at any time after REDOCEA than nondiabetic
patients. Also, each 10 years of advancing age increased
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Table III. Late carotid duplex results with time of detection and simulated time of occurrence for 121 procedures 
performed in 116 patients (Kaplan-Meier estimates with 95% CIs)
Freedom from 60% stenosis Freedom from 80% stenosis
Method 1 y 3 y 5 y 1 y 3 y 5 y
Detection* 96 (93-100) 91 (85-97) 83 (74-93) 98 (96-100) 96 (92-100) 89 (80-97)
Simulated occurrence† 92 (88-94) 85 (81-88) 80 (77-84) 96 (94-98) 92 (89-95) 88 (85-91)
*Time to first detection of either 60% or 80% stenosis after surgery (censoring at subsequent reoperation for n = 5 patients unless event beforehand).
†Simulated time of reaching either 60% or 80% stenosis after surgery (summary of 1000 replications).
Table IV. Association between death (censoring at redo) and significant covariates
Survival estimates (95% CIs)
No. % No. of events 1 y 3 y 5 y Risk ratio* P value†
All patients 199 100 50 94 (90-97) 89 (85-94) 82 (75-88)
CAD 2.77 (1.1-7.0) .024
No 38 19.2 5 97 (92-100) 95 (87-100) 87 (74-99)
Yes 160 80.8 45 93 (89-97) 88 (83-93) 80 (73-88)
*Risk ratios from a univariable Cox proportional hazards model.
†Log-rank test.
Table V. Association between stroke (censoring at redo) and significant covariates
Freedom from stroke estimates (95% CIs)
No. % No. of events 1 y 3 y 5 y Risk ratio* P value†
All patients 199 100 15 95 (92-98) 94 (91-98) 92 (88-96)
DM 3.50 (1.27-9.7) .01
No 148 74.4 7 97 (95-100) 96 (93-100) 94 (89-99)
Yes 51 25.8 8 90 (81-98) 87 (78-97) 87 (78-97)
COPD 2.87 (1.02-8.1) .036
No 158 80.2 9 97 (94-100) 96 (93-99) 95 (91-99)
Yes 39 19.8 6 90 (80-99) 86 (75-98) 82 (68-96)
Plaque histology 2.67 (0.85-8.4) .08
ASO 168 86.6 11 97 (94-100) 95 (92-97) 93 (89-98)
MIF 26 13.4 4 84 (69-98) 84 (69-98) 84 (64-98)
Age (10 y) 1.78 (1.2-2.7) .006
*Risk ratios from a univariate Cox proportional hazards models (first row is reference group).
†Log-rank test.
ASO, Arteriosclerosis obliterans; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; MIF, myointimal fibroplasia.
the likelihood of stroke at any time after REDOCEA by a
factor of 1.8. Although patients with the clinical diagnosis
of COPD were found to be 2.9 times more likely to have
a stroke at any time after REDOCEA than those without
COPD, the reasons for this relationship are not at all clear.
In summary, patients with severe recurrent carotid
stenosis tolerate REDOCEA with excellent early and late
results. Late survival is favorably associated with the
absence of CAD. Late freedom from stroke is unfavorably
influenced by the presence of diabetes mellitus, advancing
age, and COPD. We conclude that REDOCEA is safe and
clearly beneficial in selected patients with severe or symp-
tomatic internal carotid restenosis and that most of these
patients live the rest of their lives free from stroke. The
repair of serious recurrent carotid occlusive disease is suf-
ficiently safe, effective, and durable that it should not be
considered arbitrarily as a surgical contraindication.
Although recommendations about which patients should
or should not undergo REDOCEA should be individual-
ized, our data suggest that younger, nondiabetic patients
with adequate pulmonary and cardiac function are optimal
candidates for REDOCEA.
Becky Roberts helped to collect the data.
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Dr Michael Deiparine (Liberty, Mo). That was a really nice
review. I have a few kind of specific questions. One is, do you
patch routinely now, and what type of patch do you use and why
do you prefer the type you are using? The recurrences you had
with the patches were primarily in people with vein patches. Is
that because of the referral pattern, or do you think there is a dif-
ference between the synthetic and vein patches?
The second question is, what do you do with somebody who
has restenosis within a year or two who usually has intimal hyper-
plasia and has already been patched? Do you repatch them with a
bigger patch? What do you do if they come back a third time,
because we have seen that a few times?
Dr Patrick O’Hara. Our preference is to use saphenous vein
for redos, but we do not have hard data on this. We have a
prospective randomized study going on to determine whether we
can detect a difference between Dacron and saphenous vein for
primary carotid operations but not for redos. Right now our bias
is to use saphenous vein, since we think there may be a difference.
Certainly if an infection occurs in one of these, we think you are
better off with vein.
We could not detect a difference between atherosclerosis and
myointimal hyperplasia as risk factors for stroke, although the
data suggested that there were not enough events to determine
whether one form of pathology was more threatening than
another. We had very few people who had a third redo, so it is
hard to say much about that other than we tend to repatch them.
If vein is available, we would probably use vein if we can achieve
an endarterectomy plane. For the very few people in whom an
endarterectomy plane cannot technically be achieved, we will
replace the artery with an interposition vein graft.
Dr Jeb Hallett (Rochester, Minn). Pat, this is a great resource
of information. My specific question has to do with the survival
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that you showed at 5 years of 82%, which is great. If you break
the patients down into those who have known coronary disease
and those who did not, what do you tell the patients who have
had known coronary disease about what you expect in terms of
their 5-year survival? It must be different than the 82%. Did you
break them into the two groups, clinically evident coronary dis-
ease as compared with no clinically evident coronary disease look-
ing at 5-year survivals?
Dr O’Hara. Yes, we did do that. With time considerations, we
could not put all those numbers in the presentation, but they are in
the manuscript. Survival is less with coronary disease. We aggres-
sively evaluate coronary disease, not necessarily before a carotid
operation, but at least at some point, and treat it if it is indicated.
Dr Hallet. My final question: what do you recommend to the
patients in terms of antiplatelet therapy after the redo procedures?
Do you only use aspirin? Plavix? What do you recommend to your
patients?
Dr O’Hara. We have usually used aspirin. We like some form
of antiplatelet therapy. If patients can tolerate aspirin, we still pre-
fer it because it seems to be something that can be easily remem-
bered. If some patients cannot tolerate aspirin or if they are
already established on another antiplatelet regimen, we will con-
tinue that regimen, but our own preference is aspirin. 
Dr James McKinsey (Chicago, Ill). Thank you. I really enjoyed
your talk and bringing these data to us. Two simple questions.
One, your role for transposition to the external carotid rather
than reendarterectomy or interposition graft.
The second, obviously the question of the new millennium,
is the role of carotid stent angioplasty in patients with recurrent
or recurrent recurrent stenosis. Have you thought on where we
should be going with that? 
Dr O’Hara. Let me take the technical question first. Usually
we can establish a reendarterectomy plane, and then basically it is
similar to a first-go operation. Among those patients where the
plane is too thin, it is a judgment call; then we will replace the
artery with an interposition saphenous vein graft. I think there
were about six grafts in this series, so it is unusual in our practice,
although I know some people have advocated it more often. We
did not have enough events to determine whether there was a sta-
tistically significant advantage to doing it one way or another. 
Part of the purpose of this study was to establish a benchmark
of late results for comparison to the late results with interven-
tional treatment of recurrent carotid stenosis. There are no pub-
lished late results for redo carotid stenting. There is one big
multicenter study of carotid stenting that has come out that has
early results that are a little bit worse than these surgical results,
but really are comparable. I think one of the things we want to do
is establish durability data.
Dr Gregorio Sicard (St Louis, Mo). Just one quick question,
Pat. Again, a great series. Since your results with combined redo
and coronary artery disease were less than optimal when you
compared it with the straight redo, how have you changed your
practice pattern?
Dr O’Hara. I do not know that we have really changed it. We
recognize it is the kind of combination that we want to avoid
because we know that these patients do not do as well. Therefore,
our bias is not to combine a redo carotid with a coronary proce-
dure. I think most of those combined in this series were patients
who were either symptomatic or had contralateral occlusion and
a bad heart where one is forced into that approach. Our general
approach would be to avoid combined redo carotid and cardiac
operations, and maybe we should not do it at all. I don’t know,
but I think we would be in agreement that it is not an optimal
way to go.
Dr Mark Mattos (Springfield, Ill). Pat, very nice talk. I have
a comment and two questions. First of all, a recently published
multicenter study reported that the early stroke rate is 3.3% fol-
lowing carotid stenting for recurrent carotid disease. However, it
is a multicenter registry and sometimes it can be difficult to assess
those data. Similarly, in your study you performed this operation
in selected patients. You did not separate patients into asympto-
matic and symptomatic subgroups. Can you tell us if you have
data regarding your perioperative stroke risk for patients with
asymptomatic and symptomatic recurrent carotid stenosis? 
Dr O’Hara That is a good point. We did not select these
patients. These are absolutely consecutive patients from January
1, 1989, through the last day of 1999. We did break them down
into symptomatic and asymptomatic groups. Again, time did not
allow us to present that data, but in the manuscript we found that
there really was not a statistically valid difference between the two
groups, at least in our series, probably because the event rate was
pretty low.
Dr Mattos. My second question has to do with the fact that
recurrent carotid stenosis is usually fairly benign. We did a natural
history study comparing long-term stroke-free outcomes on
patients with recurrent carotid stenosis versus those patients without
restenosis. We found that the 5-year stroke-free rates between the
two groups were nearly identical, 92% versus 94%, respectively. The
question I have for you is this: do you think we should be operating
on patients with asymptomatic recurrent carotid stenosis?
Dr O’Hara. That is another issue that we did not really
address. Our tendency would be not to operate on an early recur-
rence, which is presumably myointimal disease, especially if it is
asymptomatic. We would operate on an ASO lesion later on, if it
were tight and asymptomatic, but we think that the course for
early myointimal disease is more benign.
